Pharmena Overview
- Year Founded
-
2002
- Status
-
Public
- Employees
-
7
- Stock Symbol
-
PHR
- Investments
-
1
- Share Price
-
$0.67
- (As of Thursday Closing)
Pharmena General Information
Description
Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.
Contact Information
Website
www.pharmena.euCorporate Office
- Ul. Wólczanska 178
- Lodz, 90-729
- Poland
Corporate Office
- Ul. Wólczanska 178
- Lodz, 90-729
- Poland
Pharmena Stock Performance
As of 19-Nov-2026, Pharmena’s stock price is $0.67. Its current market cap is $7.5M with 11.1M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.67 | $0.68 | $0.65 - $1.20 | $7.5M | 11.1M | 2.74K | -$0.07 |
Pharmena Financials Summary
As of 30-Jun-2026, Pharmena has a trailing 12-month revenue of $401K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 7,620 | 5,749 | 7,810 | 14,501 |
| Revenue | 401 | 419 | 67 | 298 |
| EBITDA | (879) | (838) | (829) | (2,835) |
| Net Income | (839) | (736) | (317) | (3,775) |
| Total Assets | 2,540 | 3,034 | 3,289 | 6,252 |
| Total Debt | 84 | 102 | 59 | 45 |
Pharmena Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pharmena Patents
Pharmena Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021205341-A1 | 1-methylnicotinamide for the prevention/treatment of inflammatory airway diseases | Inactive | 07-Apr-2020 | ||
| ES-2967074-T3 | 1 methylnicotinamide for the treatment of cardiovascular disease | Active | 18-Jul-2016 | ||
| JP-2019521160-A | 1-methylnicotinamide for the treatment of c-reactive protein related diseases | Pending | 18-Jul-2016 | ||
| EP-3484475-B1 | 1-methylnicotinamide for the treatment of cardiovascular disease | Active | 18-Jul-2016 | ||
| AU-2017298648-A1 | 1-methylnicotinamide for the treatment of diseases associated with c-reactive protein | Active | 18-Jul-2016 | A61K31/455 |
Pharmena Signals
Pharmena Acquisitions (1)
Pharmena’s most recent deal was a Merger/Acquisition with Cortria. The deal was made on 20-Aug-2010.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cortria | 20-Aug-2010 | Merger/Acquisition | Pharmaceuticals |
Pharmena ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Household Products
Industry
Rank
Percentile
Personal Products
Subindustry
Rank
Percentile
Pharmena FAQs
-
When was Pharmena founded?
Pharmena was founded in 2002.
-
Where is Pharmena headquartered?
Pharmena is headquartered in Lodz, Poland.
-
What is the size of Pharmena?
Pharmena has 7 total employees.
-
What industry is Pharmena in?
Pharmena’s primary industry is Personal Products.
-
Is Pharmena a private or public company?
Pharmena is a Public company.
-
What is Pharmena’s stock symbol?
The ticker symbol for Pharmena is PHR.
-
What is the current stock price of Pharmena?
As of 19-Nov-2026 the stock price of Pharmena is $0.67.
-
What is the current market cap of Pharmena?
The current market capitalization of Pharmena is $7.5M.
-
What is Pharmena’s current revenue?
The trailing twelve month revenue for Pharmena is $401K.
-
What is Pharmena’s annual earnings per share (EPS)?
Pharmena’s EPS for 12 months was -$0.07.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process